Heijden, M. S. V. D., Sarfaty, M., Caglevic, C., Gross-Goupil, M., Rosenbaum, E., Lee, J. L., Powles, T., Sridhar, S. S., Rojas, C., Shin, S. J., Robbrecht, D. G., Puente, J., Morales-Barrera, R., Su, W., Su, Y., Maillet, D., Wang, A., Bavle, A. A., Moreno, B. H., Peer, A. (2026). KEYMAKER-U04 substudy 04B: First-line (1L) enfortumab vedotin (EV) plus pembrolizumab (pembro)-based immune checkpoint inhibitor (ICI) combinations for advanced urothelial cancer (UC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.634